Template:Second-generation BTKi table: Difference between revisions
From Embryology
(Created page with "{| |+ Novel BTK inhibitors in development for treatment of CLL |- ! BTK inhibitor ! BTK binding mechanism ! Selectivity for BTK ! Relevant non-BTK targets ! Phase of clinical...") |
mNo edit summary |
||
| (19 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{| | {| | ||
|+ | |+ '''Second-generation Bruton’s Tyrosine Kinase Inhibitors (BTKi) for CCL Treatment''' | ||
|-bgcolor="CEDFF2" | |||
! width=110px|BTK inhibitor | |||
! width=150px|BTK binding mechanism | |||
! width=80px|Selectivity for BTK | |||
! width=320px|Relevant non-BTK targets | |||
! width=90px|Clinical Phase | |||
|- | |- | ||
| Acalabrutinib | |||
| Covalent, irreversible | |||
| High | |||
| N/A | |||
| II/III | |||
|-bgcolor="F5FAFF" | |||
| Zanubrutinib | |||
| Covalent, irreversible | |||
| Moderate | |||
| N/A | |||
| II/III | |||
|- | |- | ||
| Tirabrutinib | |||
| Covalent, irreversible | |||
| High | |||
| N/A | |||
| I/II | |||
|-bgcolor="F5FAFF" | |||
| Vecabrutinib | |||
| Non-covalent, reversible | |||
| Moderate | |||
| interleukin-2-inducible (ITK) | |||
N/A | | I/II | ||
|- | |||
| LOXO-305 | |||
| Non-covalent, reversible | |||
| High | |||
LYN, MEK1 | | N/A | ||
| I | |||
|-bgcolor="F5FAFF" | |||
| ARQ-531 | |||
| Non-covalent, reversible | |||
| Low | |||
| Lck/Yes novel tyrosine kinase (LYN),<br>mitogen-activated protein kinase kinase 1 (MEK1) | |||
| I | |||
|- | |- | ||
| colspan=5|Table data {{#pmid:31028669|PMID31028669}} | | colspan=5|Table data {{#pmid:31028669|PMID31028669}} | ||
|} | |} | ||
Latest revision as of 15:11, 30 April 2019
| BTK inhibitor | BTK binding mechanism | Selectivity for BTK | Relevant non-BTK targets | Clinical Phase |
|---|---|---|---|---|
| Acalabrutinib | Covalent, irreversible | High | N/A | II/III |
| Zanubrutinib | Covalent, irreversible | Moderate | N/A | II/III |
| Tirabrutinib | Covalent, irreversible | High | N/A | I/II |
| Vecabrutinib | Non-covalent, reversible | Moderate | interleukin-2-inducible (ITK) | I/II |
| LOXO-305 | Non-covalent, reversible | High | N/A | I |
| ARQ-531 | Non-covalent, reversible | Low | Lck/Yes novel tyrosine kinase (LYN), mitogen-activated protein kinase kinase 1 (MEK1) |
I |
| Table data [1] | ||||